Patents by Inventor Rohini D'Souza

Rohini D'Souza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUSTAINED RELEASE COMPOSITIONS OF 4-AMINOPYRIDINE
    Publication number: 20240050376
    Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
    Type: Application
    Filed: October 17, 2023
    Publication date: February 15, 2024
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
  • SUSTAINED RELEASE COMPOSITIONS OF 4-AMINOPYRIDINE
    Publication number: 20220323362
    Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
    Type: Application
    Filed: November 19, 2021
    Publication date: October 13, 2022
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
  • SUSTAINED RELEASE COMPOSITIONS OF 4-AMINOPYRIDINE
    Publication number: 20210338590
    Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
    Type: Application
    Filed: July 13, 2021
    Publication date: November 4, 2021
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
  • SUSTAINED RELEASE COMPOSITIONS OF 4-AMINOPYRIDINE
    Publication number: 20210085614
    Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
    Type: Application
    Filed: December 4, 2020
    Publication date: March 25, 2021
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Joseph E. Cobb, Jr., Thomas B. Gold, Rohini D'Souza, Susan L. Way
  • SUSTAINED RELEASE COMPOSITIONS OF 4-AMINOPYRIDINE
    Publication number: 20200253880
    Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
    Type: Application
    Filed: March 23, 2020
    Publication date: August 13, 2020
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
  • SUSTAINED RELEASE COMPOSITIONS OF 4-AMINOPYRIDINE
    Publication number: 20200108016
    Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 9, 2020
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
  • SUSTAINED RELEASE COMPOSITIONS OF 4-AMINOPYRIDINE
    Publication number: 20180344649
    Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
    Type: Application
    Filed: September 28, 2016
    Publication date: December 6, 2018
    Inventors: Joseph E. Cobb, Jr., Thomas B. Gold, Rohini D'Souza, Susan L. Way
  • PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS
    Publication number: 20170137799
    Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
    Type: Application
    Filed: November 18, 2016
    Publication date: May 18, 2017
    Inventors: Elliott A. GRUSKIN, Rohini D'SOUZA, Gargi ROY, Anthony O. CAGGIANO
  • Proteoglycan degrading mutants for treatment of CNS
    Patent number: 9528102
    Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: December 27, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Elliott A. Gruskin, Rohini D'Souza, Gargi Roy, Anthony O. Caggiano
  • PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS
    Publication number: 20140322192
    Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
    Type: Application
    Filed: February 24, 2014
    Publication date: October 30, 2014
    Applicant: ACORDA THERAPEUTICS, INC.
    Inventors: Elliott A. GRUSKIN, Rohini D'SOUZA, Gargi ROY, Anthony G. CAGGIANO
  • PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS
    Publication number: 20110250631
    Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
    Type: Application
    Filed: May 20, 2011
    Publication date: October 13, 2011
    Inventors: Elliott A. GRUSKIN, Rohini D'SOUZA, Gargi ROY, Anthony G. Caggiano
  • Proteoglycan degrading mutants for the treatment of CNS
    Patent number: 7968089
    Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: June 28, 2011
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Elliott A. Gruskin, Anthony O. Caggiano, Gargi Roy, Rohini D'Souza
  • Proteoglycan Degrading Mutants for the Treatment of CNS
    Publication number: 20090041728
    Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
    Type: Application
    Filed: July 3, 2008
    Publication date: February 12, 2009
    Applicant: ACORDA THERAPEUTICS, INC.
    Inventors: Elliott A. Gruskin, Rohini D'Souza, Gargi Roy, Anthony O. Caggiano
  • Proteoglycan degrading mutants for the treatment of CNS
    Patent number: 7429375
    Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: September 30, 2008
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Elliott A. Gruskin, Rohini D'Souza, Gargi Roy, Anthony O. Caggiano
  • Proteoglycan degrading mutants for the treatment of CNS
    Publication number: 20060233782
    Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
    Type: Application
    Filed: May 17, 2004
    Publication date: October 19, 2006
    Inventors: Elliott Gruskin, Rohini D'Souza, Gargi Roy, Anthony Caggiano